Clinical Trial Update: An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients Without Diabetes [Phase 3]

View source ↗

Summary

Phase 3 trial of rimonabant for nonalcoholic steatohepatitis in non-diabetic patients has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fatty Liver Disease
• Nonalcoholic Steatohepatitis

Drugs mentioned

• Rimonabant (rimonabant)

Snippet

Sponsor: Sanofi | Conditions: Fatty Liver | Phase 3 | Status: TERMINATED